

CURRICULUM VITAE



Gerassimos VOUTSINAS

Principal Investigator

Lab of Environmental Mutagenesis and Carcinogenesis

Institute of Biosciences and Applications

National Center for Scientific Research "Demokritos"

Patriarchou Grigoriou and Neapoleos str.

15310 Aghia Paraskevi Attikis, Greece

Tel: (+30 210) 650 3579, 650 3622

Fax: (+30 210) 651 1767

email: mvoutsin@bio.demokritos.gr

Home address: 74, El. Venizelou str., 15561 Holargos, Athens, Greece

Tel: (+30) 2130261751

Mob: (+30) 6976228332

List of publications online at: <http://publicationslist.org/g.e.voutsinas>

I. PERSONAL DATA

Date and place of birth: January 10, 1958, Piraeus, Greece

Nationality: Greek

Family status: Married, one daughter

Language skills: English, French

II. EDUCATION AND PROFESSIONAL APPOINTMENTS

1983: B.Sc., Dept. of Biology, Aristotle University of Thessaloniki, Greece.

1983-87: Ph.D. student, Institute of Biology, NCSR "Demokritos", Athens, Greece

1987-88: Research associate, Lab. of Environmental Mutagenesis and Carcinogenesis, Institute of Biology, NCSR "Demokritos", Athens, Greece, European Union (EU) Project "Genetic effects of environmental chemicals"

1988-91: Research associate, Lab. of Environmental Mutagenesis and Carcinogenesis, Institute of Biology, NCSR "Demokritos", Athens, Greece, EU Project "Mechanisms of induced non-disjunction and validation of tests for genomic mutations"

1991-94: Research associate, Lab. of Environmental Mutagenesis and Carcinogenesis, Institute of Biology, NCSR "Demokritos", Athens, Greece, EU Project "The detection and evaluation of aneugenic chemicals"

1993: Ph.D., Dept. of Biology, University of Patras, Greece: "Comparative study on the mutagenic activity of new anticancer alkylating agents in *Salmonella typhimurium* and *Aspergillus nidulans*"

1994-96: Research associate, Lab. of Molecular Oncology, Dept. of Medical Genetics, Faculty of Medical Sciences, University of Groningen, The Netherlands, EU

	Project “Regulation of a gene with similarity to the gene for ubiquitin-activating enzyme and with greatly reduced expression in lung cancer”
1996-99:	Research associate, Lab. of General Biology, School of Medicine, University of Patras, Greece, Greek General Secretariat of Research and Technology
	Project “Development of new biotechnological approaches for the diagnosis, prevention and therapy of inherited and acquired diseases of the Greek entity”
1997	European Collection of Animal Cell Cultures, Centre of Applied Microbiology and Research, Salisburry, UK, “Immortalization of B lymphocytes with the help of Epstein-Barr virus”
1999-2009:	Staff research scientist (grade C), Lab. of Environmental Mutagenesis and Carcinogenesis, Institute of Biology, NCSR "Demokritos", Athens, Greece
2009-to date:	Principal Investigator (grade B), (1) Lab. of Environmental Mutagenesis and Carcinogenesis, Institute of Biosciences and Applications, NCSR "Demokritos", (2) Lab. of Molecular Diagnosis of Genetic Diseases, Athens, Greece

III. TEACHING EXPERIENCE

1. Lecturer of the undergraduate course “Introduction to Molecular Biology” at the American College of Greece (2007-present day)
2. Lecturer of the undergraduate course “Environmental Health” at the American College of Greece (2013)
3. Lecturer of the post-graduate course "An Introduction to Cancer Genetics" at the Institute of Biology, NCSR "Demokritos" (1999-2008)
4. Lecturer of the post-graduate course “Principles in cancer chemotherapy” (seminar and practical exercise) (2006-2012), “Pharmacological targeting of Hsp90 in human cancers” (2010-2012), and “Molecular diagnosis of genetic diseases” (2010-2013) at the National and Kapodistrian University of Athens
5. Lecturer of the post-graduate courses “The production of mutations: endogenous and environmental factors”, “Mutation detection techniques” and “The molecular pathogenesis of cancer” at the Medical School of the University of Patras (1999-2004)
6. Lecturer at the summer schools of NCSR "Demokritos" (1999-2006)
7. High-school teacher (1997-1999)

IV. HONORS

- 3 fellowships (Greek Atomic Energy Commission, European Union, British Council)
- 4 awards for research studies presented in scientific meetings

V. INVITED SPEAKER

- In 22 scientific meetings

VI. ORGANIZING COMMITTEE MEMBER

- In 10 scientific meetings

VII. REVIEWER

- A. Articles in International Scientific Journals
 - 1. International Journal of Cancer
 - 2. Molecular and Cellular Biochemistry
 - 3. Tumor Biology
 - 4. Chemotherapy Journal
 - 5. PLoS ONE
 - 6. Nature Reviews Urology

- B. Fellowships
 - 1. International Cancer Research Technology Transfer (ICRETT) Fellowships awarded by the Union for International Cancer Control.
 - 2. Yamagiwa-Yoshida Memorial International Study (YY) Grants awarded by the Union for International Cancer Control.

VIII. OTHER ACTIVITIES

- 1. Supervisor of the Laboratory of Molecular Diagnosis of Genetic Diseases (E1609), NCSR "Demokritos", providing the appropriate service
- 2. Responsible for the ABI Prism 310 Genetic Analyzer (Applied Biosystems), the Mx3000P QPCR System (Stratagene), the Image Analysis System (Vilber Lourmat), the LAS-4000 Luminescent Image Analyzer (Fuji-Film) and the FLA-7000 Fluorescent Image Analyzing System (Fuji-Film) of the Institute of Biosciences and Applications, NCSR "Demokritos"
- 3. Committee member at the IBA, NCSR "Demokritos": 11 Supervisory committees for PhD students, eight (8) examination committees for new PhD students, six (6) committees for hiring new research associates
- 4. Supervisory committee member at Greek Universities: 11 committees for master degree, 4 PhD committees, at the National and Kapodistrian University of Athens, Greece
- 5. Supervisor of 2 post-doctoral fellows, 1 UICC fellow, 11 post-graduate students, 7 associate post-graduate students, 7 undergraduate students, 11 summer students, 14 rotating PhD students and 1 technician of the Institute of Biosciences and Applications, NCSR "Demokritos"
- 6. Member of the Hellenic Society of Biological Sciences, the Hellenic Society of Biochemistry and Molecular Biology, the Association of Medical Geneticists of Greece, the Hellenic Association for Molecular Cancer Research and the Pan-hellenic Union of Bioscientists.
- 7. Member of the Board of Directors of the Association of Medical Geneticists of Greece (2012-2013)
- 8. Member of the Scientific Committees of Tuberous Sclerosis Association of Greece (2001-present day) and Greek Alliance for Rare Diseases (2003-present day)
- 9. Member of the Board of Directors of the Greek Alliance for Rare Diseases (2003-present day)
- 10. Member of the NATO pilot study program: "Pilot Study on Advanced Risk Assessment Methods" (1999-2005)
- 11. Author of 2 articles in the Greek daily press
- 12. Author of 14 popularized scientific articles in the daily and periodical Greek press

IX. CURRENT RESEARCH INTERESTS

1. Identification and validation of drug targets for cancer therapy
2. Development and evaluation of biomarkers for diagnosis, prognosis and treatment response in human disease
3. Development of genetic testing protocols for molecular diagnosis of human genetic diseases

X. EXTRAMURAL FUNDING

Research project: *Molecular analysis of CD95 (APO-1/Fas) in breast cancer.*

Funded by the International Cancer Research and Technology Transfer Fellowships of the Union for International Cancer Control (UICC)

Fellow: Dr. Liliana Puiu

Project Leader: G.E. Voutsinas

Duration from-to: 1/9/2000 – 30/11/2000

Total funding: 3,000 €

Research project: *Regulation of apoptosis inhibition and development of resistance to chemotherapy by geldanamycin: a new chemotherapeutic drug with a specific molecular target.*

Funded by the Greek Ministry for Health and Social Solidarity

Project Leader: G.E. Voutsinas

Duration from-to: 1/1/2006 – 31/12/2007

Total funding: 14,650 €

Research project: *TSC1 and TSC2 genetic alterations in Tuberous Sclerosis.*

Funded by the Greek General Secretariat for Research and Technology

Project Leader: G.E. Voutsinas

Duration from-to: 1/4/2006 – 31/3/2008

Total funding: 11,740 €

Research project: *Development of a pharmacogenomic platform as a reliable molecular tool against human urinary bladder cancer.*

Funded by the Hellenic Society of Medical Oncology

Project Leader: G.E. Voutsinas

Duration from-to: 1/11/2007 – 31/10/2008

Total funding: 6,000 €

Research project: *Structural and functional analysis of genes involved in the PI3K signal transduction pathway in urinary bladder cancer: effects on prognosis and therapy.*

Funded by the Greek Ministry of Health and Social Solidarity

Project Leader: G.E. Voutsinas

Duration: 1/9/2008 – 31/8/2010

Total funding: 12,000 €

Research project: *Decoding of the apoptotic potential of the specific inhibitor of proteasome activity Bortezomib (Velcade) in targeted chemotherapy of human urinary bladder cancer.*

Funded by the Hellenic Society of Medical Oncology

Project Leader: D.J. Stravopodis (Dept of Biology, University of Athens, Greece)

Duration: 1/12/2009 – 31/11/2010

Total funding: 5,000 €

Research project: *Inhibition of Hsp90 as a new therapeutic tool against human urinary bladder cancer.*

Funded by the Empeirikos Foundation

Project Leader: D.J. Stravopodis (Dept of Biology, University of Athens, Greece)

Duration: 1/7/2010 – 30/6/2011

Total funding: 12,000 €

Research project: *Molecular diagnosis of Neurofibromatosis type 1.*

Funded by the American College of Greece

Project Leader: G.E. Voutsinas

Duration: 1/11/2010 – 31/10/2011

Total Funding: 10,000 €

Total funding for all the above research projects: 54,390 €

XI. RESEARCH PROJECT PROPOSALS ACCEPTED FOR FUNDING

Research Projects with the participation of G.E. Voutsinas, in different stages of implementation:

1. “Detection of New Breast and ovarian Cancer predisposing Alleles using whole genome next generation sequencing”, funded by the Greek Ministry of Education, Lifelong Learning and Religious Affairs.
2. “Genome Sequencing and Characterization of *Streptococcus macedonicus*, *Streptococcus thermophilus*, *Lactobacillus delbrueckii* subsp. *lactis* and *Lactobacillus acidipiscis*. Physiological, Evolutionary and Technological Implications”, funded by the Greek Ministry of Education, Lifelong Learning and Religious Affairs.
3. “Biological Effects of Non-Ionizing Electromagnetic Fields: A Multidisciplinary Approach”, to be funded by the Greek Ministry of Education, Lifelong Learning and Religious Affairs.
4. “Intracellular Cross-talk Between ER α/β , EGR and IGF Receptors in Development and Progression of Breast Cancer: Functional Properties, Expression of Matrix Macromolecules, Proteasome Activity and Induction of EMT”, to be funded by the Greek Ministry of Education, Lifelong Learning and Religious Affairs.

XII. PUBLICATIONS AND RELATED INFORMATION

- 41 peer-reviewed articles in International Scientific Journals
- 5 peer-reviewed book chapters (1 of them in press)
- 1 non-peer-reviewed article in a Greek Journal (in English)
- 92 abstracts in International Journal supplements or Conference Proceedings
- Impact Factor (total): 148,900
- Impact Factor (mean): 3,631
- Total number of citations (1996-2013): 615
- Self-citations of all authors excluded (1996-2013): 543
- h-factor: 14

XIII. PEER-REVIEWED ARTICLES

1. **Voutsinas, G.**, A. Kappas, N.A. Demopoulos and P. Catsoulacos (1993) Comparative study on the mutagenicity of three structurally related substituted aniline mustards in the *Salmonella*/microsome assay, *Mutation Res.* 298, 261-267. (IF: 2.220)
2. **Voutsinas, G.**, A. Kappas, N.A. Demopoulos, and P. Catsoulacos (1993) Mutagenic activity of the antitumour agent homo-aza-steroidal ester of *p*-*N,N*-bis(2-chloroethyl)amino-phenoxyacetic acid (NSC 294859) in the *Salmonella*/microsome assay, *Mutagenesis* 8, 431-435. (IF: 3.500)
3. **Voutsinas, G.**, A. Kappas, N.A. Demopoulos, and C. Camoutsis (1993) Mutagenicity of four homo-aza-steroidal esters of *m*-*N,N*-bis(2-chloroethyl)aminocinnamic acid in the Ames test, *Mutation Res.* 319, 325-329. (IF: 2.220)
4. Gichner, T., **G. Voutsinas**, A. Patrineli, A. Kappas and M.J. Plewa (1994) Antimutagenicity of three isomers of aminobenzoic acid in *Salmonella typhimurium*, *Mutation Res.* 309, 201-210. (IF: 3.902)
5. Parry, J.M., E.M. Parry, R. Bourner, ..., A. Kappas, **G. Voutsinas**, F.E. Zarani, A. Patrinelli, F. Pacchierotti, C. Tiveron and P. Hess (1996) The detection and evaluation of aneugenic chemicals, *Mutation Res.* 353, 11-46. (IF: 3.902)
6. **Voutsinas, G.**, F.E. Zarani and A. Kappas (1997) The effect of environmental aneuploidy-inducing agents on the microtubule architecture of mitotic meristematic root cells in *Hordeum vulgare*, *Cell Biology International* 21, 411-418. (IF: 1.640)
7. Vachkova, R., A. Kappas, E. Tyagunenko, M. Markaki and **G. Voutsinas** (1998) Specific recombinogenic activity of a new polyene antibiotic, *Cellular and Molecular Life Sciences* 54, 143-147. (IF: 5.615)
8. Timmer, T., P. Terpstra, A. van den Berg, P.M.J.F. Veldhuis, A. ter Elst, **G. Voutsinas**, M.M.F. Hulsbeek, T.G. Draaijers, M. Loosman, K. Kok, S.L. Naylor and C.H.C.M. Buys (1999) A comparison of genomic structures and expression patterns of two closely related flanking genes in a critical lung cancer region at 3p21.3, *Eur J Hum Genet* 7, 478-486. (IF: 4.319)
9. Athanassiadou, A., **G. Voutsinas**, L. Psiouri, E. Leroy, M.H. Polymeropoulos, A. Ilias, G.M. Maniatis and T. Papapetropoulos (1999) Genetic analysis of Parkinson's Disease families carrying the Ala53Thr mutation in the gene encoding α -synuclein, *American Journal of Human Genetics* 65, 555-558. (IF: 11.202)

10. **Voutsinas G.** (2001) Mutagenesis, apoptosis, basic relation to carcinogenic models, *Folia Histochemica et Cytobiologica* 39 suppl 2, 56-57. (IF: 1.101)
11. Michalopoulos, N.V., A. Saetta, A.Ch. Lazaris, **G. Voutsinas** and P.S. Davaris (2003) Detection of genetic abnormalities in neoplasms from Greek patients with FAP, *European Journal of Surgical Oncology* 29, 38-43. (IF: 3.184)
12. Puiu L., E. Petrakou, A. Apostolidou, A. Athanassiadou, L. Psiouri, A. Papachatzopoulou, V.G. Gorgoulis, A. Kotsinas, E. Tzoracoeleftherakis, G.M. Maniatis and **G. Voutsinas** (2003) Lack of *Fas (APO-1/CD95)* gene structural alterations or transcript variant ratio changes in breast cancer, *Cancer Letters* 194, 91-97. (IF: 4.258)
13. Korkolopoulou, P., A. Goudopoulou, **G. Voutsinas**, E. Thomas-Tsagli, E. Patsouris and A. Saetta (2004) FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathological correlations, *Urology* 63, 1198-1204. (IF: 2.424)
14. Sevinç, A., D. Yannoukakos, I. Konstantopoulou, E. Manguoglu, G. Lüleci, T. Çolak, C. Akyerli, G. Çolakoglu, M. Tez, I. Sayek, **G. Voutsinas**, G. Nasioulas, E. Papadopoulou, L. Florentin, E. Kontogianni, B. Bozkurt, N.A. Kocabas, A.E. Karakaya, I.G. Yulug and T. Özçelik (2004) No association between *RNASEL* Arg462Gln variant and breast cancer risk, *Anticancer Research* 24, 2547-2549. (IF: 1.713)
15. Saetta, A.A., A. Goudopoulou, P. Korkolopoulou, **G. Voutsinas**, E. Thomas-Tsagli, N.V. Michalopoulos and E. Patsouris (2004) Mononucleotide markers of microsatellite instability in carcinomas of the urinary bladder, *European Journal of Surgical Oncology* 30, 796-803. (IF: 3.184)
16. Bakas, P.G., A.E. Liapis, I. Zervolea, **G. Voutsinas**, D. Kletsas and G. Creatsas (2004) mRNA assessment for procollagen production in women with genuine stress urinary incontinence, *International Urogynecological Journal of Pelvic Floor Dysfunctions* 15, 429-431. (IF: 1.907)
17. Poulaki, V., C.S. Mitsiades, C. McMullan, G. Fanourakis, J. Negri, A. Goudopoulou, I.X. Halikias, **G. Voutsinas**, S. Tseleni-Balafouta, J.W. Miller and N. Mitsiades (2005) Human retinoblastoma cells are resistant to apoptosis induced by death receptors: Role of caspase-8 gene silencing, *Investigative Ophthalmology and Visual Science* 46, 358-366. (IF: 3.441)
18. Tseleni-Balafouta, S., H. Gakiopoulou, G. Fanourakis, **G. Voutsinas**, D. Balafoutas and E. Patsouris (2006) Tenascin-C protein expression and mRNA splice variants in thyroid carcinoma, *Experimental and Molecular Pathology* 80, 177-182. (IF: 2.128)
19. Tseleni-Balafouta, S., H. Gakiopoulou, G. Fanourakis, **G. Voutsinas**, H. Litsiou, E. Sozopoulos, D. Balafoutas and E. Patsouris (2006) Fibrillin expression and localization in various types of carcinomas of the thyroid gland, *Modern Pathology* 19, 695-700. (IF: 5.253)
20. Mitsiades, C.S., V. Poulaki, G. Fanourakis, E. Sozopoulos, D. McMillin, Z. Wen, **G. Voutsinas**, S. Tseleni-Balafouta and N. Mitsiades (2006) Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation, *Clinical Cancer Research* 12, 3705-3712. (IF: 7.837)
21. Mitsiades, C.S., V. Kotoula, V. Poulaki, E. Sozopoulos, J. Negri, E. Charalambous, G. Fanourakis, **G. Voutsinas**, S. Tseleni-Balafouta and N.

- Mitsiades (2006) EGFR as a therapeutic target in human thyroid carcinoma: mutational and functional analysis, Journal of Clinical Endocrinology and Metabolism 91, 3662-3666. (IF: 6.430)
22. Mitsiades, C.S., J. Negri, C. McMullan, D.W. McMillin, E. Sozopoulos, G. Fanourakis, **G. Voutsinas**, S. Tseleni-Balafouta, V. Poulaki, D. Batt and N. Mitsiades (2007) Targeting BRAFV600E in thyroid carcinoma: therapeutic implications, Molecular Cancer Therapeutics 6, 1070-1078. (IF: 5.599)
 23. Stavropoulou, C., D. Korakaki, H. Rigana, **G. Voutsinas**, M. Polyzoi, V. Georgakakos, K. Manola, C. Karageorgiou and C. Sambani (2007) Glutathione S-transferase T1 and M1 gene polymorphisms in Greek patients with multiple sclerosis: a pilot study, European Journal of Neurology 14, 572-574. (IF: 4.162)
 24. Stravopodis, D.J., L.H. Margaritis and **G.E. Voutsinas** (2007) Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex, Current Medicinal Chemistry 14, 3122-3138. (IF: 4.070)
 25. Stavropoulou, C., C. Sambani, H. Rigana, V.N. Georgakakos, **G. Voutsinas**, K.N. Manola, G.E. Pantelias and V. Makropoulos (2008) Low frequency of the glutathione-S-transferase T1-null genotype in patients with primary myelodysplastic syndrome and 5q deletion, Leukemia 22, 1643-1646. (IF: 10.164)
 26. Lampidonis, A.D., A. Argyrokastritis, D.J. Stravopodis, **G.E. Voutsinas**, T.G. Ntouropi, L.H. Margaritis, I. Bizelis and E. Rogdakis (2008) Cloning and functional characterization of the ovine Hormone Sensitive Lipase (HSL) full-length cDNAs: an integrated approach, Gene 416, 30-43. (IF: 2.196)
 27. Stravopodis, D.J., A.Z. Zapheiropoulos, **G.E. Voutsinas**, L.H. Margaritis and I.S. Papassideri (2008) A PCR-based integrated protocol for the structural analysis of the 13th exon of the human beta-myosin heavy chain gene (MYH7): Development of a diagnostic tool for HCM disease, Exp Mol Pathol 84, 245-250. (IF: 2.128)
 28. Gioni, V., T. Karabinas, **G. Voutsinas**, A.E. Roussidis, S. Papadopoulos, N.K. Karamanos and D. Kletsas (2008) Imatinib mesylate inhibits the proliferation and collagen synthesis in human breast stromal fibroblasts, Molecular Cancer Research 6, 706-714. (IF: 4.353)
 29. Lampidonis, A.D., D.J. Stravopodis, **G.E. Voutsinas**, N. Messini-Nikolaki, G.C. Stefos, L.H. Margaritis, A. Argyrokastritis, I. Bizelis and E. Rogdakis (2008) Structural characterization and functional analysis of the promoter region of *Hormone-Sensitive Lipase (HSL)* gene of the sheep (*Ovis aries*), Gene 427, 65-79. (IF: 2.196)
 30. Stravopodis, D.J., P.K. Karkoulis, E.G. Konstantakou, S. Melachroinou, D. Anastasiou, S. Kachrilas, A.D. Lampidonis, N. Messini-Nikolaki, I.S. Papassideri, G. Aravantinos, L.H. Margaritis and **G.E. Voutsinas** (2009) Grade-dependent regulation of cell cycle progression and apoptosis in response to doxorubicin in human bladder cancer cell lines, Int J Oncol 34, 137-160. (IF: 2.657)
 31. Kotoula, V., E. Sozopoulos, H. Litsiou, G. Fanourakis, T. Koletsa, **G. Voutsinas**, S. Tseleni-Balafouta, C.S. Mitsiades, A. Wellmann and N. Mitsiades (2009)

- Mutational analysis of the *BRAF*, *RAS* and *EGFR* genes in human adrenocortical carcinomas, Endocrine-Related Cancer 16, 565-572. (IF: 5.261)
32. Konstantakou, E.G., **G.E. Voutsinas**, P.K. Karkoulis, G. Aravantinos, L.H. Margaritis, and D.J. Stravopodis (2009) Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses, Int J Oncol 35, 401-416. (IF: 2.657)
33. **Voutsinas, G.E.** and D.J. Stravopodis (2009) Molecular targeting and gene delivery in bladder cancer therapy, J BUON 14 (suppl 1), S69-S78. (IF: 0.761)
34. Sozopoulos E., H. Litsiou, **G. Voutsinas**, N. Mitsiades, N. Anagnostakis, T. Tseva, E. Patsouris and S. Tseleni-Balafouta (2010) Mutational and immunohistochemical study of the PI3K/Akt pathway in papillary thyroid carcinoma in Greece, Endocr Pathol 21, 90-100. (IF=1.600)
35. **Voutsinas G.E.**, E.F. Stavrou, G. Karousos, A. Dasoula, A. Papachatzopoulou, M. Syrrou, A.J.M.H. Verkerk, P. van der Spek, G.P. Patrinos, R. Stöger and A. Athanassiadou (2010) Allelic imbalance of expression and epigenetic regulation within the alpha-synuclein wild-type and p.Ala53Thr alleles in Parkinson disease, Hum Mutat 31, 685-691. (IF: 5.213)
36. Karkoulis, P.K., D.J. Stravopodis, L.H. Margaritis and **G.E. Voutsinas** (2010) 17-Allylaminoo-17-demethoxygeldanamycin induces downregulation of critical Hsp90 protein clients and results in cell cycle arrest and apoptosis of human urinary bladder cancer cells, BMC Cancer 10:481. (IF: 3.333)
37. Stravopodis, D.J., P.K. Karkoulis, E.G. Konstantakou, S. Melachroinou, A. Thanasiopoulou, G. Aravantinos, L.H. Margaritis, E. Anastasiadou and **G.E. Voutsinas** (2010) Thymidilate synthase inhibition induces p53-dependent and p53-independent apoptotic responses in human urinary bladder cancer cell lines, J Cancer Res Clin Oncol 137, 359-374. (IF: 2.914)
38. Lampidonis, A.D., E. Rogdakis, **G.E. Voutsinas** and D.J. Stravopodis (2011) The resurgence of Hormone-Sensitive Lipase (HSL) in mammalian lipolysis, Gene 477, 1-11. (IF: 2.196)
39. Pliarchopoulou, K., **G. Voutsinas**, G. Papaxoinis, K. Florou, M. Skondra, K. Kostaki, P. Roussou, K. Syrigos and D. Pectasides (2012) Correlation of CYP1A1, GSTP1 and GSTM1 gene polymorphisms and lung cancer risk among smokers, Oncol Lett 3, 1301-1306. (IF: 0.237)
40. Karkoulis, P.K., D.J. Stravopodis, E.G. Konstantakou and **G.E. Voutsinas** (2013) Targeted inhibition of heat shock protein 90 disrupts multiple oncogenic signaling pathways, thus inducing cell cycle arrest and programmed cell death in human urinary bladder cancer cell lines, Cancer Cell International 13, 11. (IF: 2.093)
41. Stavropoulou, A.V., F. Fostira, M. Pertesi, M. Tsitlaidou, **G.E. Voutsinas**, O. Triantafyllidou, A. Bamias, M.A. Dimopoulos, E. Timotheadou, D. Pectasides, C. Christodoulou, G. Klouvas, C. Papadimitriou, T. Makatsoris, G. Pentheroudakis, G. Aravantinos, V. Karydakis, D. Yannoukakos, G. Fountzilas, I. Konstantopoulou (2013) Prevalence of BRCA1 Mutations in Familial and Sporadic Greek Ovarian Cancer Cases, PLOS ONE 8, e58182. (IF: 3.730)

XIV. PEER-REVIEWED BOOK CHAPTERS

1. Cogliano, V.J., A. Kappas, **G. Voutsinas** and G.A. Zapponi (1999) The biological basis of cancer, in: V.J. Cogliano, E.G. Luebeck and G.A. Zapponi (eds) Perspectives on Biologically Based Cancer Risk Assessment, Plenum, New York, pp 21-47.
2. McLaughlin, P.M.J., **G. Voutsinas**, K. Kok, M.G.L. Brinker, R. Vos, P. Terpstra, M.C. Harmsen, M.H.J. Ruiters, L.F.M.H. de Leij and C.H.C.M. Buys (2000) Characterization and analysis of the UBE1L promoter in lung cancer-derived cell lines and in UBE1L promoter-driven green fluorescent protein transgenic mice, in: P.M.J McLaughlin (PhD Thesis) Lung cancer associated genes studied in vitro and in vivo using transgenic animal models, Faculty of Medical Sciences, State University of Groningen, Groningen, Netherlands, pp 117-127.
3. **G. Voutsinas** (2002) Mutagenesis, Apoptosis, Basic relation to carcinogenic models, in: L. Chyczewski, J. Niklinski and E. Pluygers (eds) Endocrine Disrupters and Carcinogenic Risk Assessment, IOS Press, Amsterdam, pp 338-346.
4. **Voutsinas, G.**, A. Apostolidou and N. Spyrou (2005) New data from molecular cancer epidemiology, in: L. Edler and C. Kitsos (eds), Quantitative Methods in Cancer and Human Health Risk Assessment, John Wiley and Sons, Chichester, UK, pp. 29-41.
5. **Voutsinas, G.**, V. Biliou, J. Traeger-Synodinos, D. Synodinos, S. Youroukos, D. Yannoukakos and M. Lambrou (2013) Rare Disease patients: neglected by the health care system, in press.

XV. NON-PEER-REVIEWED ARTICLES

1. **Voutsinas, G.E.**, R. Vrtel, E. Anastasiadou and D.J. Stravopodis (2008) Molecular genetic diagnosis of the Tuberous Sclerosis Complex, BIO 28, 24-29.

XVI. LIST OF ABSTRACTS IN INTERNATIONAL JOURNAL SUPPLEMENTS OR CONFERENCE PROCEEDINGS

1. **Voutsinas, G.**, and A. Kappas (1987) Adaptive response to the mutagenic action of alkylating agents in the fungus *Aspergillus nidulans*, Abstracts of the 8th Congress of the Hellenic Society of Biological Sciences, Ioannina, Greece, p. 96-97.
2. **Voutsinas, G.** and A. Kappas (1987) Adaptive response to the mutagenic action of alkylating agents, Eur. J. Cancer Clin. Onc. 23, 1811.
3. **Voutsinas, G.** and A. Kappas (1988) On the induced adaptability of *Aspergillus nidulans* to the mutagenicity of *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine, Mutation Res. 203, 217-218.
4. **Voutsinas, G.**, A. Kappas, N.A. Demopoulos, and P. Catsoulacos (1989) Genotoxic activity of cytostatic alkylating agents in the *Salmonella*/microsome assay, Abstracts of the 11th Congress of the Hellenic Society of Biological Sciences, Komotini, Greece, p. 140-142.
5. **Voutsinas, G.**, A. Kappas, N.A. Demopoulos and P. Catsoulacos (1990) Genotoxic activity of three isomers of *N,N*-bis(2-chloroethyl)aminocinnamic acid in the *Salmonella typhimurium*/mammalian microsome test, Mutation Res. 234, 407.
6. **Voutsinas, G.**, A. Kappas, N.A. Demopoulos and C. Camoutsis (1990) The effect of different homo-aza-steroidal esters of *m-N,N*-bis(2-chloroethyl)aminocinnamic acid

- on mutation induction in the *Salmonella typhimurium*/mammalian microsome test, Mutation Res. 234, 413-414.
7. Kappas, A., M. Markaki, **G. Voutsinas**, K. Tsakiri and A. Patrineli (1991) On the validation of test systems for genomic mutations. Effects of various chemicals on mitosis of *Aspergillus nidulans*, CEC Contact Group Meeting "Genetic Effects of Environmental Chemicals", Estoril, Portugal.
 8. **Voutsinas, G.**, F.E. Zarani, and A. Kappas (1992) Effects of aneugenic chemicals on the microtubule structure in *Aspergillus nidulans* protoplasts, Abstracts of the NATO Advanced Research Workshop on Chromosome Segregation and Aneuploidy, Crete, Greece, p. 74.
 9. Kappas, A., **G. Voutsinas**, and F.E. Zarani (1992) On the mechanisms of chemically-induced aneuploidy in *Aspergillus nidulans*, CEC Contact Group Meeting "The Detection and Evaluation of Aneugenic Chemicals", Crete, Greece.
 10. Kappas, A., **G. Voutsinas** and A. Patrineli (1992) Inhibition of chemically-induced mutations by various agents, 3rd NATO-CCMS Pilot Study Meeting on Risk Assessment for Initiator and Promoter Carcinogens, Athens, Greece.
 11. **Voutsinas, G.** and A. Kappas (1993) Mutagenicity of a new antitumor agent in Salmonella, Abstracts of the XIIth Meeting of the European Association for Cancer Research, Brussels, Belgium, n° 55.
 12. Kappas, A., T. Gichner, **G. Voutsinas** and A. Patrineli (1993) Inhibition of the mutagenic action of *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine by the aminobenzoic acid isomers in Salmonella, Abstracts of the 15th Congress of the Hellenic Society of Biological Sciences, Florina-Kastoria, Greece, p. 61-63.
 13. **Voutsinas, G.**, F.E. Zarani and A. Kappas (1993) Cytological study on interphase and mitotic nuclei in *Aspergillus nidulans* germlings and protoplasts, Abstracts of the 15th Congress of the Hellenic Society of Biological Sciences, Florina-Kastoria, Greece, p. 217-220.
 14. **Voutsinas, G.**, F.E. Zarani and A. Kappas (1993) Anti-tubulin indirect immunofluorescence study in benomyl-treated meristematic cells of *Hordeum vulgare*, CEC Contact Group Meeting "The Detection and Evaluation of Aneugenic Chemicals", Barcelona, Spain.
 15. **Voutsinas, G.**, F.E. Zarani and A. Kappas (1993) Interphase and mitotic nuclei in Aspergillus, Abstracts of the Seventeenth International Congress of Genetics, Birmingham, UK, n° 30.
 16. Kappas, A. and **G. Voutsinas** (1993) Inhibition in mutagenesis and carcinogenesis, 4th NATO-CCMS Pilot Study Meeting on Risk Assessment for Initiator and Promoter Carcinogens, Lisbon, Portugal.
 17. **Voutsinas, G.** and A. Kappas (1993) Anticancer agents of similar chemical structure show different mutagenic activities, European Journal of Cancer 29A, Suppl. 6, S88.
 18. **Voutsinas, G.**, F.E. Zarani and A. Kappas (1994) Effect of aneugenic chemicals on spindle architecture in meristematic root cells of *Hordeum vulgare*, 3rd CEC Contact Group Meeting "The Detection and Evaluation of Aneugenic Chemicals", Corfu, Greece.
 19. Kappas, A. and **G. Voutsinas** (1994) Health effects of lead and aromatic hydrocarbons from vehicle emissions, Seminar of the British Hellenic Chamber of

- Commerce in "Urban Air Quality - Environmental and Health Effects of Motor Vehicle Fuel Composition", Athens, Greece.
20. Kappas, A. and **G. Voutsinas** (1994) Genetic toxicology testing of environmental mutagens and aneugens, Abstracts of the XVIth International Cancer Congress, New Delhi, India.
 21. **Voutsinas, G.**, F.E. Zarani and A. Kappas (1994) Effect of the antibiotic griseofulvin in the organization of the mitotic spindle of meristematic cells in the plant *Hordeum vulgare*, Abstracts of the 16th Congress of the Hellenic Society of Biological Sciences, Volos, Greece.
 22. Kappas, A. and **G. Voutsinas** (1994) The detection of aneugenic chemicals in Aspergillus, Abstracts of the Fifth International Mycological Congress, Vancouver, Canada.
 23. **Voutsinas, G.**, F. Zarani and A. Kappas (1995) Griseofulvin-induced disorganization of the spindle in meristematic cells of *Hordeum vulgare*, An International Conference on "Chromosome Segregation and Aneuploidy, Sorrento, Italy.
 24. **Voutsinas, G.**, A. van den Berg and C.H.C.M. Buys (1995) Characterization of the promoter region of the human *UBE1L* gene, Abstracts of the Annual Meeting of the Dutch Foundation for Medical and Health Research, Genetics Working Groups, Maastricht/ Kerkrade, The Netherlands.
 25. **Voutsinas, G.**, A. van den Berg and C.H.C.M. Buys (1996) Identification of regulatory elements in the promoter region of the human *UBE1L* gene, European Journal of Human Genetics vol. 4, suppl. 1, 64-65.
 26. **Voutsinas, G.**, K. Kok, A. van den Berg and C.H.C.M. Buys (1996) Identification of the regulatory region of the human *UBE1L* gene, which is characterized by a greatly reduced expression in lung cancer, Abstracts of the 18th Congress of the Hellenic Society of Biological Sciences, Kalamata, Greece, p. 66-68.
 27. Athanassiadou, A., **G. Voutsinas**, L. Psiouri, M. Polymeropoulos, A. Elias and T. Papapetropoulos (1998) The occurrence of α -synuclein mutation in families with Parkinson's Disease, Abstracts of the Annual Hugo Meeting - HGM'98, Turin, Italy, n° 11, p. 3.
 28. Athanassiadou, A., **G. Voutsinas**, L. Psiouri, M. Polymeropoulos, A. Elias and T. Papapetropoulos (1998) Genetic analysis of α -synuclein G209A mutation in familial Parkinson's Disease, Abstracts of the 3rd Balkan Meeting on Human Genetics, Thessaloniki, Greece, n° 0.21, p. 55.
 29. Athanassiadou, A., **G. Voutsinas**, L. Psiouri, M. Polymeropoulos, A. Ilias and T. Papapetropoulos (1998) Analysis of familial Parkinson's Disease associated with alpha-synuclein G209A mutation, American Journal of Human Genetics 63 suppl, A27, 137.
 30. Timmer, T., P. Terpstra, A. van den Berg, P.M.J.F. Veldhuis, A. ter Elst, **G. Voutsinas**, M.M.F. Hulsbeek, T.G. Draaijers, M. Loosman, K. Kok, S.L. Naylor and C.H.C.M. Buys (1998) A comparison of two closely related and flanking genes in the critical lung cancer region at 3p21.3 with respect to genomic structure and expression, American Journal of Human Genetics 63 suppl, A89, 488.

31. **Voutsinas, G.** and A. Kappas (1999) Environmental mixtures: complex patterns of exposure, CCMS/NATO Pilot Study Meeting on Advanced Cancer Risk Assessment Methods, November 13-16, 1999, Rome, Italy.
32. Konstantopoulou I., Ladopoulou A., Pantazidis A., Kotsinas A., Gorgoulis V.G., Kittas C., Tsionou C., Minaretzis D., **Voutsinas G.**, Athanassiadou A., Tzoracoelephtherakis E., Florentin L., Nounesis G., Chiotellis E., Yannoukakos D. and the Greek Consortium for BRCA1 and BRCA2 Mutation Analysis (1999) The E1038G BRCA1 polymorphism in Greece, Meeting of the Breast Cancer Linkage Consortium, Amsterdam, The Netherlands, 29 November-1 December 1999.
33. Konstantopoulou I., Ladopoulou A., Pantazidis A., Kotsinas A., Gorgoulis V.G., Kittas C., Tsionou C., Minaretzis D., **Voutsinas G.**, Athanassiadou A., Tzoracoelephtherakis E., Florentin L., Nounesis G., Chiotellis E. and D. Yannoukakos (1999) The E1038G BRCA1 polymorphism in Greece, 51st Meeting of the Hellenic Society of Biochemistry and Molecular Biology, Athens, Greece, 9-11 December 1999.
34. **Voutsinas, G.**, V. Labropoulou, L. Psiouri, A. Papachatzopoulou, A. Vassiliou, E. Tzoracoeleftherakis, G.M. Maniatis and A. Athanassiadou (2000) Polymorphisms in genes *CYP17*, *COMT*, *ER* and breast cancer risk: a multigenic study on cancer susceptibility, Proceedings of the 22nd Meeting of the Hellenic Society of Biological Sciences, Skiathos, Greece, 25-28 May 2000, p. 296-297.
35. **Voutsinas, G.** (2000) Concurrent exposures to genotoxic agents: molecular targets and their relations in carcinogenesis, CCMS/NATO Pilot Study Meeting on Advanced Cancer Risk Assessment Methods, November 17-21, 2000, Santorini, Greece.
36. Puiu, L., O. Koveou, L. Psiouri, A. Papachatzopoulou, A. Kotsinas, V.G. Gorgoulis, E. Tzoracoeleftherakis, G.M. Maniatis, A. Athanassiadou and **G. Voutsinas** (2000) The CD95 (Fas/APO-1) death receptor pathway in breast cancer, Meeting of the Panhellenic Union of Biologists "Molecular Biology - Cytogenetics in Health", 8-10 December 2000, p. 146-147.
37. Kapranos, N., A. Stratigos, E. Petrakou, **G. Voutsinas**, A. Anastasiadou, E. Kokka, A. Pagouni, E. Christofidou, Ch. Antoniou and A. Katsambas (2001) p53 gene and protein analysis in non-melanoma skin cancer, Regional Meeting International Society of Dermatology, September 6-9, 2001, Rhodes, Greece.
38. **Voutsinas G.** (2001) Mutagenesis, Apoptosis: Basic relation to carcinogenic models, *Folia Histochemica et Cytobiologica* 39, Suppl. 1, 25.
39. Puiu, L., E. Petrakou, A. Apostolidou, L. Psiouri, A. Papachatzopoulou, E. Tzoracoeleftherakis, G.M. Maniatis, A. Athanassiadou and **G. Voutsinas** (2001) Fas (APO-1/CD95) gene structural alterations and transcript variant analysis in breast cancer, Proceedings of the 53rd Meeting of the Hellenic Society of Biochemistry and Molecular Biology, Athens, Greece, 13-15 December 2001, Newsletter 48, pp 344-348.
40. Fanourakis, G., S. Tseleni-Balafouta, A. Saetta, **G. Voutsinas**, M. Miaouli and P.S. Davaris (2002) *p53* and *Fas* gene mutation detection and expression study in thyroid cancer, 8th Hellenic Conference of Pathology, Volos, Greece, 18-21 April 2002.

41. Petrakou, E., N. Kapranos, K. Anastasiadou, A. Stratigos, E. Kokka, E. Christofidou, A. Pagouni, A. Katsambas and **G. Voutsinas** (2002) *p53* mutations and expression pattern in non-melanoma skin cancer, Proceedings of the 24th Meeting of the Hellenic Society of Biological Sciences, Eretria, Euboea Island, Greece, 23-26 May 2002, p. 237-238.
42. Puiu, L., E. Petrakou, A. Apostolidou, A. Athanassiadou and **G. Voutsinas** (2002) No mutations in *Fas* (*APO-1/CD95*) or a shift towards its soluble splice variant mRNA in breast cancer, Proceedings of the 17th Meeting of the European Association for Cancer Research, Granada, Spain, 8-11 June 2002, pp. 80-81.
43. Petrakou, E., N. Kapranos, K. Anastasiadou, A. Stratigos, E. Kokka, E. Christofidou, A. Pagouni, A. Katsambas and **G. Voutsinas** (2002) *p53* mutations and expression pattern in non-melanoma skin cancer, Proceedings of the 17th Meeting of the European Association for Cancer Research, Granada, Spain, 8-11 June 2002, pp. 97.
44. Karoussos G, **G. Voutsinas**, A. Papachatzopoulou and A. Athanassiadou (2002) Analysis of allelic expression of the α -synuclein gene in Parkinson's disease, Proceedings of the 17th Meeting of the Hellenic Society for Neuroscience, University of Crete, Rethymno, Greece, 4-6 October 2002, p. 52.
45. Apostolidou, A., N. Spyrou and **G. Voutsinas** (2003) Molecular epidemiology in cancer research, International Conference on Cancer Risk Assessment, 22-24 August 2003, Athens, Greece.
46. Sambani, C., R. La Starza, **G. Voutsinas**, H. Rigana, K. Manola, I. Wlodarska and C. Mecucci (2003) The unbalanced t(1;9) in myeloproliferative disorders is a recurrent rearrangement involving the satellite II family of chromosome 1 and the satellite III of chromosome 9, Annales de Génétique – International Journal of Human and Medical Genetics 46, 140-141.
47. Fanourakis, G., A. Goudopoulou, D. Sykoutri, C.S. Mitsiades, **G. Voutsinas**, S. Tseleni-Balafouta and N. Mitsiades (2003) *B-RAF* gene is a mutational target in human thyroid cancer, Proceedings of the 55th Meeting of the Hellenic Society of Biochemistry and Molecular Biology, Athens, Greece, 13-15 November 2003, Newsletter 50, pp 168-172.
48. Labropoulou, V., D. Stefanou, V. Douris, E Adronopoulou, A. Apostolidou, **G. Voutsinas** and K. Iatrou (2005) Endoparasitization of lepidopteran insects by hymenopterans: proteins of the endosymbiotic bracovirus of the parasitic wasp *Cotesia congregata* interact with immunity-related hemocyte proteins of the parasitized host *Manduca sexta*, Proceedings of the 27th Meeting of the Hellenic Society of Biological Sciences, Nafplion, Greece, 12-14 May 2005.
49. Tseleni-Balafouta, S., G. Fanourakis, **G. Voutsinas**, H. Litsiou, C. Mitsiades, N. Mitsiades and E. Patsouris (2005) Fibrilin 1 expression in thyroid carcinomas, Virchows Archiv 447 (2), 426.
50. Parcharidou, A., D. Lianou, P. Pavlopoulos, **G. Voutsinas** and C. Sambani (2005) A new mutation in the cubilin gene, responsible for the appearance of congenital juvenile megaloblastic anaemia and proteinuria in brothers, Haema 8 supplement, p. 445.
51. Nikas, V., H. Pratsinis, G. Vlahos, A. Antsaklis, D. Kletsas and **G. Voutsinas** (2006) Targeted chemotherapy in ovarian epithelial cancer, Proceedings of the 28th

- Meeting of the Hellenic Society of Biological Sciences, Ioannina, Greece, 18-20 May 2006, p. 289-290.
52. Anastasiou D., H. Pratsinis, K. Livadas, G. Alivizatos, D. Kletsas and **G. Voutsinas** (2006) Inhibition of Hsp90 in bladder cancer, Proceedings of the 28th Meeting of the Hellenic Society of Biological Sciences, Ioannina, Greece, 18-20 May 2006, p. 7-8.
 53. Kachrilas, S., K. Livadas, G. Alivizatos and **G. Voutsinas** (2006) Study of the structure and expression of PIK3CA in urinary bladder cancer, Proceedings of the 28th Meeting of the Hellenic Society of Biological Sciences, Ioannina, Greece, 18-20 May 2006, p. 151-152.
 54. Tseleni-Balafouta, S., E. Sozopoulos, H. Litsiou, **G. Voutsinas**, G. Fanourakis, N. Mitsiades, K. Mitsiades and E. Patsouris (2006) Mutational analysis of the *BRAF* gene in human adrenocortical carcinomas, *Virchows Archiv* 448, P194.
 55. Tseleni-Balafouta, S., H. Litsiou, E. Sozopoulos, **G. Voutsinas**, G. Fanourakis, N. Mitsiades, K. Mitsiades and E. Patsouris (2006) *EGFR* mutations in thyroid carcinoma, *Pathological Anatomy Archives* 20, p. 154, P025.
 56. Kachrilas, S., D. Anastasiou, K. Livadas, G. Alivizatos, A. Papatsoris, I. Kastriotis and **G. Voutsinas** (2006) Mutation detection and expression study of the gene *PIK3CA* in urothelial bladder cancer, Proceedings of the 18th Panhellenic Congress of Urology, of the Hellenic Urological Society, Rhodes, Greece, 27 September-1 October 2006, p. 128-129, P29.
 57. **Voutsinas, G.** (2006) From phenotype to genotype: the example of Tuberous Sclerosis, 2nd Congress of the Greek Alliance for Rare Diseases, "Childhood – Rare Diseases – Orphan Drugs", Athens, Greece, 23-24 November 2006.
 58. Nikas, V., H. Pratsinis, S. Kachrilas, G. Vlahos, A. Antsaklis, D. Kletsas and **G. Voutsinas** (2006) Effect of targeted chemotherapeutic drugs on epithelial cancer cells of the ovary, 6th Panhellenic Congress on Cancer Markers and Targeted Therapy, Athens, Greece, 23-25 November 2006.
 59. Kachrilas, S., D. Anastasiou, V. Nikas, K. Livadas, G. Alivizatos and **G. Voutsinas** (2006) Structure and expression of the *PIK3CA* gene in urothelial bladder cancer, 6th Panhellenic Congress on Cancer Markers and Targeted Therapy, Athens, Greece, 23-25 November 2006.
 60. **Voutsinas, G.** (2007) Gene therapy – The future, 7th Meeting of Dermatology of the 3rd Clinic of Dermatology, Syngros Hospital, Athens, Greece, 28 April 2007, p. 18.
 61. Anastasiou, D., D.J. Stravopodis, S. Melachrinou, P. Karkoulis, E. Konstantakou, A. Lampidonis, D. Kletsas and **G. Voutsinas** (2007) Functional inhibition of Hsp90 has no effect on the levels of extracellular matrix gene transcription in human bladder cancer cells, 9th Annual Meeting of the Hellenic Research Club for Connective Tissue and Matrix Biology, Athens, Greece, p.12.
 62. Kitsos, C.P., M.S. Chalikias and **G. Voutsinas** (2007) A quantitative approach to breast cancer data, International Conference on Cancer Risk Assessment 2 (ICCRA2), Sandorini, Greece, 25-27 May 2007, p. 1-11.
 63. Tseleni-Balafouta, S., H. Litsiou, G. Fanourakis, E. Sozopoulos, **G. Voutsinas**, N. Mitsiades, K. Mitsiades and E. Patsouris (2007) *BRAF*, *EGFR* and *MET* mutations in thyroid carcinoma, 4th Scientific Congress of the Athens Medical School, Athens, 1-2 June 2007, p. 128-129, A7.

64. Louverdi, C., **G. Voutsinas**, E. Litsiou, E. Patsouris, and S. Tseleni-Balafouta (2007) Mutational analysis of the BRAF gene in various conditions of the parathyroid glands, *Virchows Archiv* 451, 273 (PPI-249).
65. Litsiou, E., G. Fanourakis, S. Vernadakis, A. Vintila, **G. Voutsinas**, E. Patsouris and S. Tseleni-Balafouta (2007) RET/PTC rearrangements in Greek patients with papillary thyroid carcinoma, *Virchows Archiv* 451, 273 (PPI-250).
66. Vrtel, R., **G. Voutsinas** and R. Vodicka (2007) Tuberous Sclerosis – Development of valid diagnostic methods at a minimum cost, Mutation Detection – IX International Symposium on Mutations in the Genome, 23-27 September 2007, Xiamen, China, p. 59, P24.
67. Lampidonis, A., A. Argyrokastritis, D. Stravopodis, **G. Voutsinas**, L.H. Margaritis, I. Bizelis and E. Rogdakis (2007) Structural characterization and functional analysis of the promoter region of *Hormone-Sensitive Lipase (HSL)* gene of the sheep (*Ovis aries*), *Animal Science Review* 33, 30-31.
68. Gioni, V., T. Karabinas, **G. Voutsinas**, A.E. Roussidis, S. Papadopoulos, N.K. Karamanos and D. Kletsas (2007) Imatinib mesylate inhibits the proliferation and collagen synthesis in human breast stromal fibroblasts, 59th Meeting of the Hellenic Society of Biochemistry and Molecular Biology, 7-9 December 2007, Athens, Greece, p. 107.
69. Vrtel, R., **G. Voutsinas**, R. Vodicka, H. Filipova, D. Konvalinka, A. Santava and J. Santavy (2008) Development of reliable and economical DNA diagnostics in tuberous sclerosis, Fifth International Symposium on Genetics, Health and Disease (V-ISGHD), February 17-19, 2008, Amritsar, India, p. 74, P54.
70. Avgeris, S., R. Vrtel, D. Anastasiou, P. Papadopoulou, R. Vodicka, E. Anastasiadou, D.J. Stravopodis and **G.E. Voutsinas** (2008) Development of a protocol for molecular diagnosis of tuberous sclerosis, Proceedings of the 30th Scientific Conference of Hellenic Association for Biological Sciences, 22-24 May 2008, Thessaloniki, Greece, p. 40-41.
71. Stravopodis, D.J., D. Wang, I.S. Papasideri, L.H. Margaritis and **G.E. Voutsinas** (2008) Reconstitution of erythropoietin signalling pathway in non-erythroid cellular environment, Proceedings of the 30th Scientific Conference of Hellenic Association for Biological Sciences, 22-24 May 2008, Thessaloniki, Greece, p. 454-455.
72. Vrtel, R., H. Filipova, R. Vodicka, **G. Voutsinas**, D. Konvalinka, A. Santava and J. Santavy (2008) DNA diagnostics in tuberous sclerosis - development of reliable and economical test, 40th European Human Genetics Conference (ESHG 2008), May 31-June 3, 2008, Barcelona, Spain, P06.290.
73. Stavropoulou, C., E. Rigana, V.N. Georgakakos, **G. Voutsinas**, K.N. Manola, G. Pantelias, V. Makropoulos, A. Symeonidis, A. Kouraklis, N. Zoumbos , N. Vyniou, E. Plata, A. Galanopoulos, T. Marinakis, N. Anagnostopoulos, P. Roussou, A. Fragou, A. Parcharidou, V. Papa, A. Lazaridou, C. Mitsouli, C. Megalakaki, M. Bakiri, N. Laoutaris, H. Papadaki, G. Bourikas, M. Protopappa, D. Georgiadou, P. Zikos, C. Sambani (2008) Polymorphisms of detoxification genes in patients with primary myelodysplastic syndrome, 19th Panhellenic Hematological Congress, November 19-22, 2008, Athens, Greece.
74. Gioni, V., T. Karabinas, **G. Voutsinas**, A.E. Roussidis, S. Papadopoulos, N.K. Karamanos and D. Kletsas (2009) Imatinib mesylate inhibits proliferation and

- collagen synthesis in human breast stromal fibroblasts, 15th Panhellenic Congress of Clinical Oncology, March 26-28, 2009, Athens, Greece.
75. Stavropoulou, C., S. Zachaki, K. Manola, **G. Voutsinas**, H. Orphanidou, V. Georgakakos and C. Sambani (2009) Association of NQO1 C609T polymorphism with chromosomes 5 and/or 7 abnormalities in patients with MDS/AML, 10th International Symposium on Myelodysplastic Syndromes, May 6-9, 2009, Patras, Greece, Leukemia Research 33, suppl. 1, S45-S46.
76. Anastasiou, D.K., D.J. Stravopodis and **G.E. Voutsinas** (2009) DNA methyltransferase and histone deacetylase inhibitors synergize to induce apoptotic death in human urinary bladder cancer cells, Proceedings of the 31st Scientific Conference of Hellenic Association for Biological Sciences, 14-16 May 2009, Patras, Greece, p. 14-15.
77. Gioni, V., Th. Karabinas, **G. Voutsinas**, A.E. Roussidis, S. Papadopoulos, N.K. Karamanos and D. Kletsas (2009) Imatinib mesylate inhibits the proliferation and collagen synthesis in human breast stromal fibroblasts, Proceedings of the 31st Scientific Conference of Hellenic Association for Biological Sciences, 14-16 May 2009, Patras, Greece, p. 60-61.
78. Karkoulis, P.K., D.J. Stravopodis, E.G. Konstantakou, L.H. Margaritis and **G.E. Voutsinas** (2009) 17-AAG induces cell cycle arrest and apoptosis in human urinary bladder cancer cell lines due to down-regulation of multiple Hsp90 clients in the Akt signalling pathway, Proceedings of the 31st Scientific Conference of Hellenic Association for Biological Sciences, 14-16 May 2009, Patras, Greece, p. 124-125.
79. Konstantakou, E.G., **G.E. Voutsinas**, P.K. Karkoulis, G. Aravantinos, L.H. Margaritis and D.J. Stravopodis (2009) Cisplatin-induced apoptosis of human bladder cancer cells is associated with p53-dependent and p53-independent regulatory responses, Proceedings of the 31st Scientific Conference of Hellenic Association for Biological Sciences, 14-16 May 2009, Patras, Greece, p. 172-173.
80. Setta-Kaffetzi, N., A. Thanasiopoulou, M. Roumpelaki, A. Samara, E.G. Konstantakou, G.E. Voutsinas, N. Anagnou, K. Dimas, D.J. Stravopodis and E. Anastasiadou (2009) Xenograft animal models for the in vivo live imaging of human tumors, Proceedings of the 31st Scientific Conference of Hellenic Association for Biological Sciences, 14-16 May 2009, Patras, Greece, p. 318-319.
81. **Voutsinas G.E.** and Stravopodis D.J. (2009) Molecular targeting and gene delivery in bladder cancer therapy, 3rd Seminar of the Balkan Society of Oncology, 10-12 September 2009, Volos, Greece.
82. Karkoulis P.K., Stravopodis D.J., Konstantakou E.G., Melachroinou S., Anastasiou D., Margaritis L.H. and **Voutsinas G.E.** (2009) Hsp90 drug targeting in bladder cancer cells, 14th World Congress on Advances in Oncology and 12th International Symposium on Molecular Medicine, 15-17 October 2009, Loutraki, Greece, International Journal of Molecular Medicine 24 (suppl), S31.
83. Karkoulis P.K., Stravopodis D.J., Margaritis L.H. and **Voutsinas G.E.** (2009) Inhibition of multiple signaling pathways by 17-allylaminio-17-demethoxygeldanamycin in human urinary bladder cancer cells, 60th Meeting of the Hellenic Society of Biochemistry and Molecular Biology, 20-22 November 2009, Athens, Greece, p. 137.

84. Karkoulis P.K., Stravopodis D.J., Margaritis L.H. and **Voutsinas G.E.** (2009) Pharmacological targeting of Hsp90 molecular chaperone in human urinary bladder cancer cells, 1st International Conference on Molecular Cancer Research, 27-29 November 2009, Athens, Greece, p. 32.
85. **Voutsinas G.** (2009) Molecular diagnosis of rare hematological disorders, 4th Conference of the Greek Alliance for Rare Diseases "Rare Diseases with Hematologic Manifestations – New Therapeutic Approaches", Athens, Greece, 11-12 December 2009.
86. Karkoulis P.K., Stravopodis D.J., Velentzas A.D. and **Voutsinas G.E.** (2011) 17-DMAG induces functional impairment of multiple heat shock protein 90-assisted signaling pathways in human urinary bladder cancer cells, 62nd Conference of the Greek Society for Biochemistry and Molecular Biology, 9-11 December 2011, Athens, Greece.
87. **Voutsinas, G.**, J. Traeger-Synodinos, D. Stardelis, A. Grypari, R. Rodopoulou, D. Synodinos, S. Youroukos, M. Lambrou, D. Yannoukakos (2012) A patient-initiated registry for Rare Diseases: the experience of the Greek Alliance for Rare Diseases (PESPA), 6th European Conference on Rare Diseases & Orphan Products, 23-25 May 2012, Brussels, Belgium.
88. Koutlis, G., E. Spyropoulos, E.G. Konstantakou, D. Velentzas, **G.E. Voutsinas**, K. Sfiniadakis, D.J. Stravopodis (2013) Comparative study of Vimentin, E-Cadherin, P-Cadherin and N-Cadherin expression profiles in human urothelial bladder carcinomas, 18th Congress of Balkan Military Medical Committee, 22-26 May 2013, Istanbul, Turkey.
89. Konstantakou, E.G., **G.E. Voutsinas**, G. Aravantinos, E. Anastasiadou and D.J. Stravopodis (2013) Bortezomib-induced eradication of bladder cancer cells depends on apoptosis, autophagy and signaling deregulation, but does not require p53 activity, International Workshop on "Ageing and Cancer Cell Biology: Convergent and Divergent Molecular Mechanisms", 27-29 June 2013, Athens, Greece.
90. Avgeris S., D.J. Stravopodis, D. Yannoukakos and **G.E. Voutsinas** (2013) Μοριακή διάγνωση της Οζώδους Σκλήρυνσης, 1st National Conference of the Association of Medical Geneticists of Greece, 30-31 May-1 June 2013, Athens, Greece.
91. Peristeri E., S. Avgeris, P. Papadopoulou, A. Misseyanni, D.J. Stravopodis and **G.E. Voutsinas** (2013) Establishment and validation of a genetic test for identification of Neurofibromatosis type I, 1st National Conference of the Association of Medical Geneticists of Greece, 30-31 May-1 June 2013, Athens, Greece.
92. **Voutsinas G.** (2013) The Genetics of Tuberous Sclerosis Complex, 6th Conference of the Greek Alliance for Rare Diseases "Rare Diseases in Northern Greece", Thessaloniki, Greece, 11-12 October 2013.